• Percentage of patients satisfied with 5mg treatment [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
• Percentage of patients obtaining additional benefit with increase to 10mg dose [ Time Frame: week 12 ] [ Designated as safety issue: No ]

• Assess: most bothersome OAB symptom at baseline; % satisfied with 5mg treatment; % obtain additional benefit with increase to 10mg dose
• satisfaction with treatment for patients completing 12 weeks of treatment; safety and tolerability of 5 and 10mg Vesicare

To evaluate the safety and efficacy of solifenacin succinate in subjects with overactive bladder symptoms (urgency, with or without urge incontinence, usually with frequency and nocturia).

Study included a 24 week extension that did not occur due to FDA approval of the product.

Inclusion Criteria:

• Symptoms of OAB (urgency, with or without urge incontinence, usually with frequency and nocturia) for ≥3 or more months.
• Patients may be included if they are on another OAB medication; however, patients must washout from other OAB medications for at least 7 days prior to receiving solifenacin succinate. Previous non-drug treatment of OAB is allowed if it has been established at least 4 weeks prior to study entry and is continued throughout the study.

Exclusion Criteria:

• -Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor
• Evidence of urinary tract infection; chronic inflammation such as interstitial cystitis and bladder stones
• Clinically significant outflow obstruction (benign prostatic hyperplasia)